This important donation from Cancer Research & Genetics UK will help support our preclinical studies, investigating how we can improve the efficacy of targeted therapeutic agents to treat prostate cancer and advance our understanding of how this disease develops therapeutic resistance. This donation will facilitate the purchase of a tissue slicer, that can be used to generate thin sections of prostate cancer specimens for culture in plastic dishes. By taking this approach, we can rapidly determine the initial response of prostate tumours to therapeutic interventions ex vivo, yet advantageously in the context of an intact tumour microenvironment. By establishing the therapeutic responses of prostate cancer cells and their surrounding microenvironment to new therapeutic strategies, we hope to preclinically test/validate new therapeutic approaches to inform the design of future clinical trials that can benefit patients with prostate cancer.
– Dr Helen Pearson, Cardiff University